FERTI-LILY Safety Study
A Prospective, 1-Arm, Open Label, Non-Randomized Study of the FERTI-LILY Conception Cup Device to Assess Label Comprehension, Device Usability and Safety in Women
1 other identifier
observational
18
1 country
1
Brief Summary
The study is a prospective, 1-arm, open label, nonrandomized, single center study designed to evaluate label comprehension, device usability and safety of the FERTI·LILY Conception Cup. The primary safety endpoint will be an assessment of reported adverse events. Subjects will be screened -10 (±3) days prior to the baseline visit. At baseline, 15-20 subjects meeting the inclusion/exclusion criteria will be provided with a FERTI·LILY Conception Cup device and instructions for using the device. Subjects will participate in a label comprehension protocol that includes the physician confirmation that they have adequate comprehension to enroll. If not, a screen failure form is completed. Subjects will agree to try and use the device within 2 weeks of disposition therefore at baseline a two-week visit is scheduled. In the event they do not use the device within the two-week period the follow up visit can be rescheduled based on the visit window of +14 days. If it is not used within 4 weeks, the PI will have the subject return to the site to authorize another two-week period that will be captured as unscheduled follow up visit. The subject should complete the Device Experience Survey after each device use. The Device Experience Survey will be returned at this time, and adverse events will be assessed.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jul 2022
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 29, 2022
CompletedFirst Submitted
Initial submission to the registry
September 1, 2022
CompletedFirst Posted
Study publicly available on registry
September 6, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 20, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
September 21, 2022
CompletedApril 6, 2023
September 1, 2022
2 months
September 1, 2022
April 4, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Safety of Device
Occurrence of device-related adverse events.
6 weeks
Secondary Outcomes (2)
Label Comprehension Assessment Protocol
6 weeks
Device Usability
6 weeks
Study Arms (1)
Study Population
Up to 20 subjects will be recruited from the patient population at the Principal Investigator's clinic. Subject recruitment will end once 15 evaluable subjects have completed the study.
Interventions
The FERTI-LILY Conception Cup is indicated for over-the-counter (OTC) home use by couples trying to conceive. The FERTI·LILY device OTC contains a cervical cap attached to a stem. The FERTI-LILY Conception Cup is intended to push semen towards the cervix as an aid in conception. It is designed to be inserted vaginally after intercourse and left in place for 20-60 minutes. The device is recommended to be used during the ovulatory phase of the menstrual cycle. It is not to be left in place for longer than six hours. The device may be re-used up to 18 times or over 6 cycles.
Eligibility Criteria
Subjects who meet study eligibility criteria will be recruited from the patient population of the Principle Investigator's clinic.
You may qualify if:
- Subject is a female volunteer, age ≥ 18 years.
- Subject is willing and able to provide written informed consent for study participation.
- Subject agrees to use the FCC device as directed.
- Subject agrees to complete all study-related assessments.
- Subject agrees to try to use the cup within two weeks of disposition.
- PI confirms that the subject had the adequate label comprehension to enroll in the study.
You may not qualify if:
- Subject has a medical condition or other factor that, in the opinion of the investigator, would contraindicate participation in the study.
- Subject has active bacterial vaginosis infection or vaginismus.
- Subject has an abnormal clinically significant Pap Smear diagnosis.
- Subject has a history of endometriosis.
- Subject has any contraindications with the Instructions for Use.
- Subject has an allergy to silicone.
- Subject is pregnant or lactating.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Boca Raton Obstetrics and Gynecology
Boca Raton, Florida, 33431, United States
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 1, 2022
First Posted
September 6, 2022
Study Start
July 29, 2022
Primary Completion
September 20, 2022
Study Completion
September 21, 2022
Last Updated
April 6, 2023
Record last verified: 2022-09